Actively Recruiting
A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer
Led by The University of Hong Kong · Updated on 2025-06-12
716
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the live birth rate in women undergoing natural cycle frozen-thawed embryo transfer (FET) with and without oral dydrogesterone as luteal phase support. This randomized double-blinded controlled trial aims to test the hypothesis that oral dydrogesterone may increase the live birth rate in natural cycle FET. The study is conducted at the Centre of Assisted Reproduction and Embryology, The University of Hong Kong-Queen Mary Hospital. Participants will be randomly assigned to one of two groups: one receiving oral dydrogesterone 10mg three times daily and the other receiving a placebo, both starting the day after the luteinizing hormone (LH) surge or human chorionic gonadotropin (hCG) induced ovulation, for two weeks. Embryo transfer is performed on the third or sixth day after the LH surge or hCG trigger depending on embryo stage. Women are closely monitored with pelvic ultrasounds and blood tests to track ovulation and hormone levels. During the study, participants will undergo daily monitoring leading up to ovulation and embryo transfer. Pregnancy testing occurs 16 days after FET, and pregnancy outcomes are followed for analysis. Researchers measure live birth rate as the primary outcome and also track clinical pregnancy rate, ongoing pregnancy rate, and pregnancy loss. The study includes detailed monitoring and follow-up over several weeks post-transfer to assess the effects of the treatment.
CONDITIONS
Brief Title
Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women younger than 43 years at time of stimulated IVF
- Undergoing frozen-thawed embryo transfer with early cleavage embryos or blastocysts after thawing
You will not qualify if you...
- Requiring hormonal replacement cycles
- Using donor oocytes or embryos
- Undergoing preimplantation genetic testing
- Having untreated hydrosalpinx prior to FET
- Refusing to join the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 weeks
Participants receive oral dydrogesterone or placebo starting one day after the LH surge or hCG trigger for two weeks as luteal phase support during the frozen-thawed embryo transfer cycle.
Daily medication for 2 weeks, embryo transfer occurs 3 to 7 days after LH surge or hCG trigger depending on embryo type
Duration - Up to 10 months after recruitment
Participants undergo a urine pregnancy test 16 days after the frozen-thawed embryo transfer and pregnancy outcomes are monitored.
1 pregnancy test visit and ongoing pregnancy follow-up visits as needed
Trial Site Locations
Total: 1 location
1
Department of Obstetrics and Gynaecology
Hong Kong, Hong Kong, China
Actively Recruiting
Research Team
E
Ernest HY Ng, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here